TLSA TLSA

Tiziana Life Sciences Share Price

0.71
-0.0355 (-4.76%)
Upgrade to Real-Time
Afterhours (Closed)
0.71
Volume 43,855
Bid Price 0.5505
Ask Price 0.7439
News -
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Tiziana Life Sciences Ltd TLSA NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.0355 -4.76% 0.71 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.72 0.69 0.766 0.71 0.7455
Trades Volume VWAP Dollar Volume Avg Volume
175 43,855  0.7218553  31,657 -
Last Trade Time Type Quantity Stock Price Currency
16:50:03 6  0.7395 USD

Period:

Draw Mode:

Tiziana Life Sciences Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 72.61M 102.27M 63.63M  -  - -0.24 -3.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - 37.10%

more financials information »

News Tiziana Life Sciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

TLSA Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohn's Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products.


Your Recent History
NASDAQ
TLSA
Tiziana Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.